Daily Stock Analysis, DRRX, DURECT Corp, priceseries

DURECT Corp. Daily Stock Analysis
Stock Information
Open
0.66
Close
0.66
High
0.68
Low
0.64
Previous Close
0.66
Daily Price Gain
0.00
YTD High
0.90
YTD High Date
May 6, 2019
YTD Low
0.48
YTD Low Date
Jan 2, 2019
YTD Price Change
0.12
YTD Gain
22.55%
52 Week High
1.68
52 Week High Date
Jul 16, 2018
52 Week Low
0.46
52 Week Low Date
Dec 28, 2018
52 Week Price Change
-1.01
52 Week Gain
-60.36%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 12. 2017
1.25
Jul 27. 2017
1.81
32 Trading Days
44.92%
Link
LONG
Sep 29. 2017
1.77
Oct 12. 2017
1.91
9 Trading Days
8.04%
Link
LONG
Nov 16. 2017
0.96
Nov 30. 2017
1.08
9 Trading Days
12.35%
Link
LONG
Feb 21. 2018
1.12
Mar 26. 2018
1.95
23 Trading Days
74.42%
Link
Company Information
Stock Symbol
DRRX
Exchange
NasdaqGM
Company URL
http://www.durect.com
Company Phone
4087771417
CEO
Felix Theeuwes
Headquarters
California
Business Address
10260 BUBB RD, CUPERTINO, CA 95014
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001082038
About

DURECT Corp. operates as a biopharmaceutical company. It engages in the development of therapeutics based on its proprietary drug delivery technology platforms. Its brands include ALZET, a osmotic pumps, which is used in laboratory research; and LACTEL, a biodegradable polymers, which is used by pharmaceutical and medical device clients for use as raw materials in their products. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery; and REMOXY ER, an investigational extended release pain relief drug. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.